Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 4
2007 5
2008 20
2009 33
2010 30
2011 23
2012 35
2013 47
2014 42
2015 39
2016 54
2017 44
2018 46
2019 42
2020 41
2021 47
2022 49
2023 52
2024 36

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

609 results

Results by year

Filters applied: . Clear all
Page 1
Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Haffner MC, et al. Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16. Nat Rev Urol. 2021. PMID: 33328650 Free PMC article. Review.
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, Sheu KM, Cheng D, Ta L, Varuzhanyan G, Huang A, Xu R, Zeng Y, Borujerdpur A, Bayley NA, Noguchi M, Mao Z, Morrissey C, Corey E, Nelson PS, Zhao Y, Huang J, Park JW, Witte ON, Graeber TG. Chen CC, et al. Cancer Cell. 2023 Dec 11;41(12):2066-2082.e9. doi: 10.1016/j.ccell.2023.10.009. Epub 2023 Nov 22. Cancer Cell. 2023. PMID: 37995683 Free PMC article.
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. Labrecque MP, et al. J Clin Invest. 2019 Jul 30;129(10):4492-4505. doi: 10.1172/JCI128212. J Clin Invest. 2019. PMID: 31361600 Free PMC article.
Molecular events in neuroendocrine prostate cancer development.
Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, Wang Y. Wang Y, et al. Nat Rev Urol. 2021 Oct;18(10):581-596. doi: 10.1038/s41585-021-00490-0. Epub 2021 Jul 21. Nat Rev Urol. 2021. PMID: 34290447 Free PMC article. Review.
Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, Thomas GV, Caruso B, Thompson RF, Wood MA, Hipfinger C, Hammond SA, Graff JN, Xia Z, Moran AE. Guan X, et al. Nature. 2022 Jun;606(7915):791-796. doi: 10.1038/s41586-022-04522-6. Epub 2022 Mar 23. Nature. 2022. PMID: 35322234 Free PMC article.
The Landscape of Circular RNA in Cancer.
Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, Robinson DR, Nesvizhskii AI, Chinnaiyan AM. Vo JN, et al. Cell. 2019 Feb 7;176(4):869-881.e13. doi: 10.1016/j.cell.2018.12.021. Cell. 2019. PMID: 30735636 Free PMC article.
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK. Bhatia V, et al. Nat Commun. 2023 Apr 11;14(1):2041. doi: 10.1038/s41467-023-37874-2. Nat Commun. 2023. PMID: 37041154 Free PMC article.
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.
Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold JM, Meekin J, Chang CY, Carrasco RA, Breen S, Cheung CS, Endlich-Frazier A, Clark B, Chu NJ, Vantellini A, Martin PL, Hoover CE, Riley K, Sweet SM, Chain D, Kim YJ, Tu E, Harder N, Phipps S, Damschroder M, Gilbreth RN, Cobbold M, Moody G, Bosco EE. Zanvit P, et al. J Clin Invest. 2023 Nov 15;133(22):e169655. doi: 10.1172/JCI169655. J Clin Invest. 2023. PMID: 37966111 Free PMC article.
609 results